Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

July 31, 2019

Progentec Granted $1.7M to Validate Measure of SLE Disease Activity

News

Progentec, a company developing new diagnostic technologies for chronic conditions, has been awarded $1.7 million to validate its blood biomarker test as an accurate tool for measuring disease activity ... Read more

July 29, 2019

‘Lupus Low Disease Activity State’ Linked to Reduced Healthcare Costs, Study Confirms

News

Attaining a low disease state — deemed Lupus Low Disease Activity State or LLDAS — has become a major goal for treatment for people with systemic lupus erythematosus. Researchers ... Read more

July 8, 2019

Lupus Research Alliance, Bristol-Myers Join to Advance Phase 2 Study of Oral Treatment for Lupus Nephritis

News

The Lupus Research Alliance (LRA) and its affiliate Lupus Therapeutics have expanded a collaboration with Bristol-Myers Squibb to help assess the company’s investigational agent BMS-986165 as a possible treatment for lupus ... Read more

June 14, 2019

KZR-616 Shows Early Promise in Treatment of Active SLE

News

KZR-616, a selective immunoproteasome inhibitor, is safe, well-tolerated, and effectively reduces disease activity in patients with active systemic lupus erythematosus (SLE), preliminary Phase 1b data show. The findings were ... Read more

May 8, 2019

Mallinckrodt Completes Enrollment in Phase 4 Trial Testing Acthar Gel in SLE Patients

News

Mallinckrodt Pharmaceuticals has completed enrollment for its Phase 4 clinical trial evaluating the safety and effectiveness of H.P. Acthar Gel (repository corticotropin injection) in patients with persistently active systemic lupus erythematosus (SLE). The company expects the ... Read more

March 25, 2019

Equillium Plans to Open Phase 1 Trial of EQ001 in Lupus Nephritis Patients Toward End of Year

News

Equillium announced that it is planning to test EQ001, its monoclonal antibody, in a Phase 1b trial as a potential therapy for patients with refractory lupus nephritis, among the most frequent and ... Read more

March 11, 2019

Lupus Therapeutics, Takeda Launch Phase 1 Trial of TAK-079 for Moderate to Severe SLE

News

The Lupus Research Alliance and its affiliate, Lupus Therapeutics, have partnered with Takeda Pharmaceutical to conduct a Phase 1 clinical trial testing Takeda’s investigational antibody TAK-079 for the treatment of systemic lupus erythematosus (SLE) ... Read more

March 8, 2019

Physical Fitness Linked with Better Quality of Life in Women with SLE

News

Physical fitness, particularly muscle strength and cardiorespiratory fitness, are associated with better quality of life scores in women with systemic lupus erythematosus (SLE), a study reports. The study, “Association ... Read more

November 28, 2018

Phase 1 Trial Testing Safety of Potential Lupus Therapy, LY3361237, Underway

News

A Phase 1 clinical trial evaluating Eli Lilly’s investigational therapy LY3361237 in healthy people has dosed its first participant, Sanford Burnham Prebys Medical Discovery Institute (SBP) announced. The treatment is ... Read more

November 12, 2018November 12, 2018

Stem Cell Treatment Seen to Benefit Lupus Patients in Phase 1 Trial, New Study Opening

News

A single infusion of mesenchymal stem cells (MSCs) — those that make cells of the cartilage, bone, and fat — decreased the number of auto-reactive immune cells in difficult-to-treat systemic lupus ... Read more

This is a short description about myself and what this site is about. I hope you enjoy being here!

Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Progentec Granted $1.7M to Validate Measure of SLE Disease Activity

‘Lupus Low Disease Activity State’ Linked to Reduced Healthcare Costs, Study Confirms

Lupus Research Alliance, Bristol-Myers Join to Advance Phase 2 Study of Oral Treatment for Lupus Nephritis

KZR-616 Shows Early Promise in Treatment of Active SLE

Mallinckrodt Completes Enrollment in Phase 4 Trial Testing Acthar Gel in SLE Patients

Equillium Plans to Open Phase 1 Trial of EQ001 in Lupus Nephritis Patients Toward End of Year

Lupus Therapeutics, Takeda Launch Phase 1 Trial of TAK-079 for Moderate to Severe SLE

Physical Fitness Linked with Better Quality of Life in Women with SLE

Phase 1 Trial Testing Safety of Potential Lupus Therapy, LY3361237, Underway

Stem Cell Treatment Seen to Benefit Lupus Patients in Phase 1 Trial, New Study Opening

Pin It on Pinterest